Šalis: Airija
kalba: anglų
Šaltinis: HPRA (Health Products Regulatory Authority)
Alginic acid; Calcium carbonate; Magnesium carbonate
Bayer Limited
A02AD
Alginic acid; Calcium carbonate; Magnesium carbonate
625/73.5/150 milligram(s)
Chewable tablet
Product not subject to medical prescription
Combinations and complexes of aluminium, calcium and magnesium compounds
Not marketed
2009-02-06
BCH22023 1/5 PACKAGE LEAFLET: INFORMATION FOR THE USER RENNIE DUAL ACTION TABLETS Calcium carbonate, Magnesium carbonate, Alginic acid Chewable tablets READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must contact a doctor if you do not feel better or if you feel worse after 14 days. WHAT IS IN THIS LEAFLET 1. What Rennie Dual Action Tablets are and what they are used for 2. What you need to know before you take Rennie Dual Action Tablets 3. How to take Rennie Dual Action Tablets 4. Possible side effects 5. How to store Rennie Dual Action Tablets 6. Contents of the pack and other information 1. WHAT RENNIE DUAL ACTION TABLETS ARE AND WHAT THEY ARE USED FOR Rennie Dual Action tablets provide relief from heartburn and acid indigestion. Rennie Dual Action tablets work in two different ways: 1. Alginic acid forms a protective barrier in the stomach to stop acid escaping upwards, soothing that burning pain in your chest 2. Calcium carbonate and magnesium carbonate provide rapid and long lasting neutralization of excess acid in the stomach 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE RENNIE DUAL ACTION TABLETS DO NOT TAKE RENNIE DUAL ACTION TABLETS: • If you have severe kidney disease or suffer from kidney stones. • If you have high calcium or low phosphate levels in the blood. • If you are allergic to any of the ingredients. BCH22023 2/5 WARNINGS AND PRECAUTIONS: As with other antacid products, taking these tablets can mask the symptoms of other, more serious, underlying medical conditions. If symptoms persist after fourteen days consult your doctor. Patients aged 55 year Perskaitykite visą dokumentą
Health Products Regulatory Authority 10 November 2022 CRN00D61K Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Rennie Dual Action Chewable Tablets Calcium carbonate 625mg Magnesium carbonate 73.5mg Alginic acid 150mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each chewable tablet contains: Alginic acid 150mg, calcium carbonate 625mg and heavy magnesium carbonate 73.50mg. Excipients: each chewable tablet contains 14 mg sodium as well as sucrose (230 mg) and glucose (555.22 mg). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Chewable tablet Off white, speckled circular tablet, flat on both sides with a bevelled edge. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of complaints resulting from gastro-oesophageal reflux and hyperacidity, such as regurgitation and heartburn. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The usual dose is 2 tablets to be chewed. It should preferably be taken one hour after meals and before going to bed. An additional dose can also be taken in between in the case of heartburn. The maximum dose of 8 grams calcium carbonate (corresponding to 12 tablets) per day should not be exceeded and should not be taken continuously for longer than 2 weeks. Only for use by adults and children over 12 years of age. As with all antacids, if symptoms persist despite 14 days of continuous therapy, diagnostic measures are strongly recommended in order to rule out a more serious disease. Pregnant women should limit the duration of treatment this medicinal product is used as symptoms subside, and it should not be used for more than two weeks. For Special warning and precautions for use please also see section 4.4. 4.3 CONTRAINDICATIONS Severe renal insufficiency Hypercalcaemia and/or conditions resulting in hypercalcaemia Pre-existing hypophosphataemia Nephrolithiasis due to calculi containing calcium deposits Hypersensitivity to the active substances or to any of the excipients 4.4 SPECIAL WARNINGS AND PRECAUTION Perskaitykite visą dokumentą